Dozulé, Normandy, France--Pfizer Animal Health and The Hippolia
Foundation announced today the formation of a strategic partnership to
advance equine health through research and educational programmes.
The Hippolia Foundation – a network of leading French equine
institutions together with international partners – will collaborate
with Pfizer to accelerate advancement in innovation on the diagnosis,
treatment and prevention of equine disease. The Hippolia partner
organisations and Pfizer are initially investing more than $5 million
over three years.
“This is an excellent example of a public/private initiative to advance
our scientific knowledge and improve animal health and welfare,” said
Pierre Lekeux, President, The Hippolia Foundation.
The two principal areas of collaboration to be developed between Pfizer
and The Hippolia Foundation will focus on respiratory disorders, and on
infectious diseases.
“This is a particularly synergistic partnership,” said Alejandro Bernal,
Area President, Pfizer Animal Health, Europe, Africa and Middle East.
“Together, The Hippolia Foundation and Pfizer have created a partnership
based on what is today the largest equine research network worldwide.
Both parties will benefit from the combined expertise and resources in
the interests of accelerating pioneering equine research.”
Pfizer Animal Health has a broad and leading portfolio of parasiticides,
pharmaceuticals, and core and speciality vaccines. The latter group
includes Equip for Flu, Tetanus and EHV as well as vaccines which
address emerging disease - importantly, West Nile virus.
In November 2011, the company opened a new global Equine Research Center
at its worldwide veterinary medicine research and development
headquarters in greater Kalamazoo, Michigan. Pfizer Animal Health is
dedicated to providing comprehensive solutions for equine health,
including an integrated offer of vaccines, therapeutics, diagnostics,
practice management and services.
Founded in 2011 and located in Normandy - at the centre of one of
Europe’s most recognised regions for competition horses - The Hippolia
Foundation supports and promotes the development of research programmes,
training and services at an international level, particularly on issues
of health, welfare and performance in horses.
The Normandy site has established a reputation as a world-class facility
undertaking leading-edge research on racehorses (thoroughbred and
standardbred) but also on sport horses. The Hippolia Foundation also has
existing partnerships with hospitals, and it is expected that its
research could possibly have comparative translational aspects that
would benefit human health as well as equine.
About Pfizer Animal Health
Pfizer Animal Health, a business unit of Pfizer Inc, is a world leader
in the discovery, development and manufacture of innovative animal
health vaccines, medicines, and diagnostic products. Pfizer Animal
Health invests more in research and development than any other animal
health company. We work to assure a safe, sustainable global food supply
from healthy beef and dairy cattle, swine, poultry and fish while
helping dogs, cats and horses live healthier longer lives. We strive to
be the animal health company that provides full healthcare solutions to
veterinarians, livestock producers, and pet owners. To learn more, visit www.pfizeranimalhealth.com.
For further press information contact
Anne-France Quentric
T: 0033 1580 753 40
M: 0033 6855 395 87
Anne-France.Quentric@pfizer.com